Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
暂无分享,去创建一个
C. Cannon | L. Wallentin | R. Becker | R. Lopes | R. Harrington | H. Katus | P. Steg | S. Bansilal | S. James | R. Storey | Benjamin Neely | A. Himmelmann | S. Wiviott | Y. Shimada | S. Husted
[1] Jeroen J. Bax,et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.
[2] C. Held,et al. Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). , 2015, The American journal of cardiology.
[3] Hani Jneid,et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Forc , 2012, Journal of the American College of Cardiology.
[4] T. Lauer,et al. Kardiologische Aspekte der präoperativen Risikostratifizierung , 2011 .
[5] C. Cannon,et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. , 2010, Journal of the American College of Cardiology.
[6] Claes Held,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.
[7] E. Antman,et al. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis , 2009, Journal of the American College of Cardiology.
[8] A. Skene,et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. , 2009, American heart journal.
[9] S. Steinhubl,et al. Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use. , 2008, American heart journal.
[10] Ralph D'Agostino,et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. , 2007, The New England journal of medicine.
[11] P. Sandset,et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. , 2006, European heart journal.
[12] A. Kastrati,et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. , 2006, JAMA.
[13] R. Storey,et al. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses , 2005, Platelets.
[14] R. Califf,et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials , 2002, The Lancet.